Clinical trial

TMC114-TiDP3-C176 - A Study in Healthy Volunteers Investigating the Bioequivalence Between Two Commercially Available 400-mg Tablets to One New 800-mg Tablet of Darunavir (DRV) in the Presence of Low-dose Ritonavir Under Fed and Fasted Conditions

NCT01308658

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Darunavir (DRV) Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record ritonavir Normalized identity: ritonavirView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

TMC114-TiDP3-C176 - A Study in Healthy Volunteers Investigating the Bioequivalence Between Two Commercially Available 400-mg Tablets to One New 800-mg Tablet of Darunavir (DRV) in the Presence of Low-dose Ritonavir Under Fed and Fasted Conditions

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2011-01-01

PhasePHASE1

Conditions

Healthyunresolved

Interventions

Darunavir (DRV)DRUG

ritonavirDRUG · verified · RxNorm: ritonavir

Sponsors & collaborators

Tibotec Pharmaceuticals, Irelandlead sponsor

Mapped research locations

BerlinGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01308658 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.